Latest / Bloomberg Intelligence / Timblerlake on V-GO Insulin Delivery Device (Correct) (Audio)

Transcript

Timblerlake on V-GO Insulin Delivery Device (Correct) (Audio) · Bloomberg Intelligence

• 0:00
  Speaker 1: Now on Bloomberg Radio, we take stock of healthcare. The
• 0:04
  Speaker 1: issue of drug pricing has been at the forefront, certainly
• 0:06
  Speaker 1: in the political realm for the last few months. We're
• 0:08
  Speaker 1: living in a very special time in the history of
• 0:12
  Speaker 1: the pharmaceutical industry. Let me three percent of all biotechts
• 0:15
  Speaker 1: that start actually get a drug approved. It's a very
• 0:17
  Speaker 1: hard thing to do. Bloomberg taking stop healthcare and focus
• 0:21
  Speaker 1: on Bloomberg Radio. Yes, healthcare in focus and diabetes in focus.
• 0:26
  Speaker 1: Turning our attention now to those people who at some
• 0:30
  Speaker 1: point may have to inject themselves up to twenty eight
• 0:33
  Speaker 1: times a week with insulin. Here to tell us more
• 0:36
  Speaker 1: about some of the alternatives is John Timberlake. He is
• 0:39
  Speaker 1: the president and the chief executive of Valeritas, and he
• 0:43
  Speaker 1: joins me now. John, thank you very much for being here.
• 0:46
  Speaker 1: Thank you, thanks for having me. Well, you know, just
• 0:48
  Speaker 1: before we get into the details of some of the
• 0:51
  Speaker 1: v GO system, maybe just tell people a little bit
• 0:55
  Speaker 1: about your background, because you've been involved in diabetes even
• 0:58
  Speaker 1: before you came to Valeritas in two thousand six. That's correct.
• 1:03
  Speaker 1: I have spent the last twenty five years focused in
• 1:05
  Speaker 1: the air diabetes. I spent fifteen years within the company
• 1:08
  Speaker 1: pharmaceutical called Santa Fee responsible for um the diabetes portfolio
• 1:13
  Speaker 1: from the phase one up through and on the market.
• 1:16
  Speaker 1: And I came to Valaritas ten years ago because I
• 1:19
  Speaker 1: saw this technology as something really could net an unmet
• 1:21
  Speaker 1: need for the Type two patient with diabetes. All right,
• 1:24
  Speaker 1: let's talk about this technology. This is the v GO
• 1:27
  Speaker 1: technology and it is wearable on the skin and it's
• 1:31
  Speaker 1: just about two inches long. What it actually does it do?
• 1:34
  Speaker 1: So the Vego is a very simple, easy to use product.
• 1:38
  Speaker 1: It is a wearable patch that is um completely mechanical.
• 1:43
  Speaker 1: There's no electronics, there's no batteries. The patient can put
• 1:46
  Speaker 1: this on their on their body, leave the house and
• 1:48
  Speaker 1: have all the ins and they need for the day.
• 1:50
  Speaker 1: So it delivers a constant flow of insulin throughout twenty
• 1:53
  Speaker 1: four hours. And then when the patient eats, they can
• 1:56
  Speaker 1: very discreetly and easily give themselves additional insulin around meal
• 1:59
  Speaker 1: times by simply clicking buttons on the device through their clothing.
• 2:03
  Speaker 1: So they could be sitting at a restaurant or the cafeteria.
• 2:06
  Speaker 1: And there's a really big social stigma with people taking
• 2:08
  Speaker 1: type or Type two is taken insulin in public because
• 2:11
  Speaker 1: society has kind of blamed them for having type two diabetes. Well,
• 2:14
  Speaker 1: tell people a little bit more about it, like what
• 2:16
  Speaker 1: is it that causes type two diabetes and what is
• 2:19
  Speaker 1: the addressable market. So diabetes, type two diabetes is really
• 2:22
  Speaker 1: as a multi factory disease. It's both the combination the
• 2:25
  Speaker 1: body not using the instant the body can make and
• 2:28
  Speaker 1: the body not making enough insulin. So it's a very large,
• 2:32
  Speaker 1: unfortunate opportunity because there's so many people who have type
• 2:35
  Speaker 1: two diabetes. In the United States alone, there were twenty
• 2:38
  Speaker 1: two million people who have diabetes, six million of them
• 2:41
  Speaker 1: are type twos. Are taking insulint through injections of these
• 2:45
  Speaker 1: patients do not reach the reach their seem to control.
• 2:48
  Speaker 1: And so that's a huge unmet need of more and
• 2:50
  Speaker 1: happening in patients who could benefit from a product like
• 2:52
  Speaker 1: the Vego. The Food and Drug Administration has given approval
• 2:57
  Speaker 1: for Vigo. Correct, that's correct. The Vego is commercial rights.
• 3:00
  Speaker 1: It's it's the only product approved by the FDA that
• 3:02
  Speaker 1: has a mechanical delivery of incident for both background and
• 3:04
  Speaker 1: meal time insulin. It's also approved by the European Committee.
• 3:08
  Speaker 1: And what kind of efficacy. Have you found in UH
• 3:12
  Speaker 1: in patients that use this versus let's say, injectable insulin.
• 3:16
  Speaker 1: We've demonstrated quite a breath of clinical studies showing the
• 3:21
  Speaker 1: patients who are taking injectable insulin when they go to
• 3:23
  Speaker 1: the vego, they significally lower their glucose. They do that
• 3:26
  Speaker 1: with less prescribed insulin, so that allows them to actually
• 3:29
  Speaker 1: get better results using less insulin and actually saving the
• 3:32
  Speaker 1: payer system money because of that. Um it's very interesting.
• 3:35
  Speaker 1: Of those six million people who take insulin, A large
• 3:38
  Speaker 1: study asked these patients who are prescribed meal time insulin
• 3:41
  Speaker 1: and sevy two percent said they never take ins and
• 3:43
  Speaker 1: out of the house, So it's a huge problem for
• 3:46
  Speaker 1: these patients. By wearing the vego underneath their clothing and
• 3:49
  Speaker 1: simply being able to click buttons when they eat gives
• 3:52
  Speaker 1: them the ability to control their diabetes better. What about
• 3:55
  Speaker 1: the cost of vigo their beauty. The good thing about
• 3:57
  Speaker 1: the vego is this is a single use, fullly disposable product,
• 4:01
  Speaker 1: so it's not classified as a durable medical equipment, which
• 4:04
  Speaker 1: is very very important for the reimbursement. Therefore, it's actually reimbursed,
• 4:08
  Speaker 1: distributed and fulfilled more like a drug at the pharmacy.
• 4:11
  Speaker 1: Ninety five percent of our product was fulfilled the pharmacy. Therefore,
• 4:14
  Speaker 1: those patients go to the pharmacy with the prescription and
• 4:17
  Speaker 1: they pay a monthly co pay. There's no large deductibles
• 4:19
  Speaker 1: and co insurance like there is with durable equipment and
• 4:22
  Speaker 1: durable insulin pumps. A couple of questions, so about the company,
• 4:26
  Speaker 1: I know you did an alternative initial public offering, I
• 4:29
  Speaker 1: believe back in May correct. What is an alternative public
• 4:33
  Speaker 1: offering and why did you go that route? So essentially,
• 4:36
  Speaker 1: an alternative public offering is essentially a company merging in
• 4:39
  Speaker 1: with an already public company and then taking over and
• 4:42
  Speaker 1: using that company as a public company. So you're right,
• 4:45
  Speaker 1: Laritas now is a public company. We are traded with
• 4:47
  Speaker 1: the chicker v l r X, and we did that
• 4:50
  Speaker 1: because we're a company now that's at a commercial stage.
• 4:52
  Speaker 1: We're an execution stage. We have regatory approval in the
• 4:55
  Speaker 1: US and in um Europe. We are producing this at
• 4:59
  Speaker 1: commercial scale. All we have a large clerical, steady data
• 5:02
  Speaker 1: that's been published, and we have good reimbursement. So really
• 5:04
  Speaker 1: it's the right time to access the public markets to
• 5:07
  Speaker 1: help support the growth of the company, And what about distribution.
• 5:10
  Speaker 1: Who's you have a partner or you're doing that. We
• 5:12
  Speaker 1: do know we're actually doing this ourselves today yet. But
• 5:14
  Speaker 1: because the product is distributed through the pharmacy channel, we
• 5:17
  Speaker 1: basically can provide that product to any pharmacy in the
• 5:19
  Speaker 1: country through the wholesalers. I want to thank you very
• 5:22
  Speaker 1: much for coming in and sharing this information with us, right,
• 5:25
  Speaker 1: Thank you very much. John Timberlake is the president and
• 5:28
  Speaker 1: the chief executive of Valeritas talking about a new wearable device.
• 5:34
  Speaker 1: It's called Vigo. You wear it on the skin under clothing.
• 5:37
  Speaker 1: It's about two inches long, and it fills you with
• 5:41
  Speaker 1: the insulin that you need all day long. This is
• 5:44
  Speaker 1: taking Stock. I'm pim Fox, and this is Bloomberg.